Opinion statement Tumor necrosis factor-α (TNF-α) is an inflammatory cytokine that plays a
major role during the initiation and perpetuation of inflammatory bowel disease (IBD). Anti …

Gastroenterol Clin N Am 41 (2012) 411–428 doi: 10.1016/j. gtc. 2012.01. 012 gastro.
theclinics. com 0889-8553/12/$–see front matter© 2012 Elsevier Inc. All rights reserved. of …

Anti-tumor necrosis factor (anti-TNF) therapy has been successfully used as first-line
biologic treatment for moderate-to-severe inflammatory bowel disease (IBD), in both “step …

Background Failure of anti-TNF treatment in inflammatory bowel disease (IBD) patients can
take on several forms, each posing distinct etio-pathogenic considerations and management …

Crohn's disease and ulcerative colitis are chronic inflammatory gastrointestinal disorders
which often result in significant morbidity or surgery. Current treatment options are not …

After the introduction of anti-tumor necrosis factor (anti-TNF) agents, the clinical outcome of
patients with Inflammatory Bowel Disease (IBD) has improved significantly. However, use of …

Introduction During the last decades, biologics have revolutionized the treatment of Crohn's
disease and ulcerative colitis. Even though the inflammatory bowel disease (IBD) …

Although tumor necrosis factor (TNF)-α antagonists play a critical role in the treatment of
moderate-to-severe inflammatory bowel disease (IBD), several factors can impact treatment …

Introduction: Crohn's disease (CD) and ulcerative colitis (UC) are chronic disabling
conditions. Monoclonal antibody therapy directed against tumor necrosis factor-alpha (anti …

Despite the evolution in inflammatory bowel disease (IBD) management during the last 20
years owing to the advent of new advanced therapies, anti-TNF agents still remain the …